<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00630253</url>
  </required_header>
  <id_info>
    <org_study_id>MT2000-09</org_study_id>
    <secondary_id>0001M34441</secondary_id>
    <nct_id>NCT00630253</nct_id>
  </id_info>
  <brief_title>Cytoxan, Fludara, and Antithymocyte Globulin Conditioning Followed By Stem Cell Transplant in Treating Fanconi Anemia</brief_title>
  <official_title>A Study of Cyclophosphamide, Fludarabine, and Antithymocyte Globulin Followed by Matched Sibling Donor Hematopoietic Cell Transplantation in Patients With Fanconi Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving chemotherapy, such as cyclophosphamide and fludarabine, before a donor stem&#xD;
      cell transplant helps to remove the patient's cells to allow for the transplant cells to take&#xD;
      and grow. It also helps stop the patient's immune system from rejecting the donor's stem&#xD;
      cells. When the healthy stem cells from a donor are infused into the patient, they may help&#xD;
      the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.&#xD;
      Sometimes the transplanted cells can make an immune response against the body's normal cells.&#xD;
      Giving antithymocyte globulin and removing the T cells from the donor cells before transplant&#xD;
      and giving cyclosporine before and after transplant may stop this from happening.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects of cyclophosphamide, fludarabine,&#xD;
      and antithymocyte globulin followed by donor stem cell transplant and to see how well it&#xD;
      works in treating patients with Fanconi anemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine the probability of engraftment in patients with Fanconi anemia treated with&#xD;
           cyclophosphamide, fludarabine phosphate, and antithymocyte globulin followed by&#xD;
           HLA-genotypically identical sibling donor hematopoietic stem cell transplantation that&#xD;
           is T-cell depleted.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To evaluate the incidence of acute graft-versus-host disease (GVHD) and chronic GVHD in&#xD;
           patients treated with this regimen.&#xD;
&#xD;
        -  To evaluate the incidence of regimen-related toxicity in these patients.&#xD;
&#xD;
        -  To evaluate the 1-year survival of patients treated with this regimen.&#xD;
&#xD;
        -  To evaluate the incidence of late secondary malignancies (e.g., squamous cell carcinoma&#xD;
           of the head and neck or cervix) in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
        -  Preparative cytoreductive therapy: Patients receive cyclophosphamide IV over 2 hours on&#xD;
           days -6 to -3 and fludarabine phosphate IV over 30 minutes and anti-thymocyte globulin&#xD;
           IV over 4-6 hours on days -6 to -2.&#xD;
&#xD;
        -  T-cell depleted donor hematopoietic stem cell transplantation: Patients undergo T-cell&#xD;
           depleted donor bone marrow or umbilical cord blood stem cell transplantation on day 0.&#xD;
           Patients also receive filgrastim (G-CSF) IV beginning on day 1 and continuing until&#xD;
           blood counts recover.&#xD;
&#xD;
        -  Graft-versus-host disease prophylaxis: Patients receive cyclosporine IV over 2 hours or&#xD;
           orally every 8-12 hours beginning on day -3 and continuing until day 100, followed by a&#xD;
           taper. Patients will receive Mycophenolate Mofetil (MMF) therapy beginning on day -3&#xD;
           through day +30 or for 7 days after engraftment, whichever day is later, if no acute&#xD;
           GVHD. Engraftment is defined as 1st day of 3 consecutive days of absolute neutrophil&#xD;
           count [ANC] &gt; 0.5 x 10^9/L.&#xD;
&#xD;
      After completion of study therapy, patients are followed periodically.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 17, 2000</start_date>
  <completion_date type="Actual">October 10, 2020</completion_date>
  <primary_completion_date type="Actual">October 10, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Experiencing Graft Failure</measure>
    <time_frame>From Day 1 to event, assessed up to100 days</time_frame>
    <description>graft failure = absolute neutrophil count (ANC) &lt;5 x 10^8/L and an acellular bone marrow aspirate/biopsy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Acute Graft-Versus-Host Disease (GVHD)</measure>
    <time_frame>Day 42</time_frame>
    <description>Acute Graft-Versus-Host Disease is a severe short-term complication created by infusion of donor cells into a foreign host.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Overall Survival</measure>
    <time_frame>1 Year</time_frame>
    <description>The percentage of people in a study or treatment group who are alive for a certain period of time after they were diagnosed with or treated for a disease, such as cancer. Also called survival rate.&#xD;
Overall survival will be defined as time from enrollment to date of death or censored at the date of last documented contact for patients still alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Chronic Graft-Versus-Host Disease (GVHD)</measure>
    <time_frame>1 Year</time_frame>
    <description>Chronic Graft-Versus-Host Disease is a severe long-term complication created by infusion of donor cells into a foreign host.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Transplant Related Deaths</measure>
    <time_frame>Day 100</time_frame>
    <description>In the field of transplantation, toxicity is high and all deaths without previous relapse or progression are usually considered as related to transplantation</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Fanconi Anemia</condition>
  <arm_group>
    <arm_group_label>Marrow Isolex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>bone marrow processed using Isolex 300i (for patients enrolled through April 2010)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UCB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>No processing Notes: sibling donor UCB is used as the stem cell source and co-enroll for unlicensed UCB registry</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Marrow Clinimax</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>bone marrow processed using CliniMACS (for patients enrolled beginning with the August 2010 protocol version)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Anti-Thymocyte Globulin</intervention_name>
    <description>30 mg/kg/day will be administered after MP on days -6, -5, -4, -3 and -2.</description>
    <arm_group_label>Marrow Clinimax</arm_group_label>
    <arm_group_label>Marrow Isolex</arm_group_label>
    <arm_group_label>UCB</arm_group_label>
    <other_name>ATG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>5 mg/kg is to be given as a 2 hour infusion, Days -6 through -3.</description>
    <arm_group_label>Marrow Clinimax</arm_group_label>
    <arm_group_label>Marrow Isolex</arm_group_label>
    <arm_group_label>UCB</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>35 mg/m^2 intravenously (IV) on days -6 through -2.</description>
    <arm_group_label>Marrow Clinimax</arm_group_label>
    <arm_group_label>Marrow Isolex</arm_group_label>
    <arm_group_label>UCB</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Bone marrow or umbilical cord blood infusion on day 0.</description>
    <arm_group_label>Marrow Clinimax</arm_group_label>
    <arm_group_label>Marrow Isolex</arm_group_label>
    <arm_group_label>UCB</arm_group_label>
    <other_name>HSCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>Methylprednisolone (MP) 2 mg/kg/day intravenously every 24 hours will be given from day -6 until day -2 as a premedication for ATG.</description>
    <arm_group_label>Marrow Clinimax</arm_group_label>
    <arm_group_label>Marrow Isolex</arm_group_label>
    <arm_group_label>UCB</arm_group_label>
    <other_name>MP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <description>5 mcg/kg per day intravenously (IV) continue until Absolute neutrophil count &gt; or = 2.5 x 10^9/L</description>
    <arm_group_label>Marrow Clinimax</arm_group_label>
    <arm_group_label>Marrow Isolex</arm_group_label>
    <arm_group_label>UCB</arm_group_label>
    <other_name>G-CSF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine</intervention_name>
    <description>Cyclosporine IV over 2 hours or orally every 8-12 hours beginning on day -3 and continuing until day 100, followed by a taper.</description>
    <arm_group_label>Marrow Clinimax</arm_group_label>
    <arm_group_label>Marrow Isolex</arm_group_label>
    <arm_group_label>UCB</arm_group_label>
    <other_name>CSA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Day -3 through day +30 or for 7 days after engraftment, whichever day is later, if no acute GVHD. Engraftment is defined as 1st day of 3 consecutive days of absolute neutrophil count [ANC] &gt; 0.5 x 10^9/L. MMF will be given at a dose of 15 mg/kg/dose every 8 hours PO (to a maximum dose of 1 gram).</description>
    <arm_group_label>Marrow Clinimax</arm_group_label>
    <arm_group_label>Marrow Isolex</arm_group_label>
    <arm_group_label>UCB</arm_group_label>
    <other_name>MMF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must be &lt;60 years of age with a diagnosis of Fanconi Anemia (FA).&#xD;
&#xD;
          -  Patients must have an HLA-A, B, DRB1 identical sibling donor. Patients and donors will&#xD;
             be typed for HLA-A and B using serological or molecular techniques and for DRB1 using&#xD;
             high resolution molecular typing.&#xD;
&#xD;
          -  Patients with FA must have moderately severe aplastic anemia (AA), early&#xD;
             myelodysplastic syndrome (MDS) with no excess blasts with or without chromosomal&#xD;
             abnormalities.&#xD;
&#xD;
               -  In patients &lt;18 years of age, moderately severe aplastic anemia is defined as&#xD;
                  having at least one of the following:&#xD;
&#xD;
                    -  platelet count &lt;40 x 10^9/L&#xD;
&#xD;
                    -  absolute neutrophil count (ANC) &lt;10 x 10^8/L&#xD;
&#xD;
                    -  Hgb &lt;9 g/dL&#xD;
&#xD;
               -  In patients 18-60 years of age, moderately severe aplastic anemia is defined as&#xD;
                  having at least one of the following:&#xD;
&#xD;
                    -  platelet count &lt;20 x 10^9/L&#xD;
&#xD;
                    -  absolute neutrophil count ANC &lt;5 x 10^8/L&#xD;
&#xD;
                    -  Hgb &lt;8 g/dL&#xD;
&#xD;
               -  Early myelodysplastic syndrome, with multilineage dysplasia with &lt; 5% blasts,&#xD;
                  with or without chromosomal anomalies.&#xD;
&#xD;
          -  Adequate major organ function including:&#xD;
&#xD;
               -  Cardiac: ejection fraction &gt;45%&#xD;
&#xD;
               -  Hepatic: no clinical evidence of hepatic failure (e.g. coagulopathy, ascites)&#xD;
&#xD;
               -  Karnofsky performance status &gt;70% or Lansky &gt;50%&#xD;
&#xD;
          -  Women of child bearing age must be using adequate birth control and have a negative&#xD;
             pregnancy test.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active bacterial infection within one week of hematopoietic cell transplant (HCT)&#xD;
&#xD;
          -  Active fungal infection at time of HCT.&#xD;
&#xD;
          -  Late MDS with greater than 5% blasts in bone marrow.&#xD;
&#xD;
          -  Acute myelogenous leukemia (AML) or history of AML&#xD;
&#xD;
          -  Malignant solid tumor (e.g. squamous cell carcinoma of the head/neck/cervix) within 2&#xD;
             years of HCT.&#xD;
&#xD;
          -  Pregnant or lactating female.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margaret L. MacMillan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Masonic Cancer Center, University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 5, 2008</study_first_submitted>
  <study_first_submitted_qc>March 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2008</study_first_posted>
  <results_first_submitted>September 10, 2021</results_first_submitted>
  <results_first_submitted_qc>October 8, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 12, 2021</results_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fanconi anemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fanconi Syndrome</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Fanconi Anemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 3, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/53/NCT00630253/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Marrow Isolex</title>
          <description>bone marrow processed using Isolex 300i (for patients enrolled through April 2010)</description>
        </group>
        <group group_id="P2">
          <title>Umbilical Cord Blood (UCB) Arm</title>
          <description>No processing</description>
        </group>
        <group group_id="P3">
          <title>Marrow Clinimax</title>
          <description>bone marrow processed using CliniMACS (for patients enrolled beginning with the August 2010 protocol version)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Marrow Isolex</title>
          <description>bone marrow processed using Isolex 300i (for patients enrolled through April 2010)</description>
        </group>
        <group group_id="B2">
          <title>UCB Arm</title>
          <description>No processing</description>
        </group>
        <group group_id="B3">
          <title>Marrow Clinimax</title>
          <description>bone marrow processed using CliniMACS (for patients enrolled beginning with the August 2010 protocol version)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Experiencing Graft Failure</title>
        <description>graft failure = absolute neutrophil count (ANC) &lt;5 x 10^8/L and an acellular bone marrow aspirate/biopsy</description>
        <time_frame>From Day 1 to event, assessed up to100 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Marrow Isolex</title>
            <description>bone marrow processed using Isolex 300i (for patients enrolled through April 2010)</description>
          </group>
          <group group_id="O2">
            <title>UCB Arm</title>
            <description>No processing</description>
          </group>
          <group group_id="O3">
            <title>Marrow Clinimax</title>
            <description>bone marrow processed using CliniMACS (for patients enrolled beginning with the August 2010 protocol version)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Graft Failure</title>
          <description>graft failure = absolute neutrophil count (ANC) &lt;5 x 10^8/L and an acellular bone marrow aspirate/biopsy</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Acute Graft-Versus-Host Disease (GVHD)</title>
        <description>Acute Graft-Versus-Host Disease is a severe short-term complication created by infusion of donor cells into a foreign host.</description>
        <time_frame>Day 42</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Marrow Isolex</title>
            <description>bone marrow processed using Isolex 300i (for patients enrolled through April 2010)</description>
          </group>
          <group group_id="O2">
            <title>UCB Arm</title>
            <description>No processing</description>
          </group>
          <group group_id="O3">
            <title>Marrow Clinimax</title>
            <description>bone marrow processed using CliniMACS (for patients enrolled beginning with the August 2010 protocol version)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Acute Graft-Versus-Host Disease (GVHD)</title>
          <description>Acute Graft-Versus-Host Disease is a severe short-term complication created by infusion of donor cells into a foreign host.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Overall Survival</title>
        <description>The percentage of people in a study or treatment group who are alive for a certain period of time after they were diagnosed with or treated for a disease, such as cancer. Also called survival rate.&#xD;
Overall survival will be defined as time from enrollment to date of death or censored at the date of last documented contact for patients still alive.</description>
        <time_frame>1 Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Marrow Isolex</title>
            <description>bone marrow processed using Isolex 300i (for patients enrolled through April 2010)</description>
          </group>
          <group group_id="O2">
            <title>UCB Arm</title>
            <description>No processing</description>
          </group>
          <group group_id="O3">
            <title>Marrow Clinimax</title>
            <description>bone marrow processed using CliniMACS (for patients enrolled beginning with the August 2010 protocol version)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Overall Survival</title>
          <description>The percentage of people in a study or treatment group who are alive for a certain period of time after they were diagnosed with or treated for a disease, such as cancer. Also called survival rate.&#xD;
Overall survival will be defined as time from enrollment to date of death or censored at the date of last documented contact for patients still alive.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Chronic Graft-Versus-Host Disease (GVHD)</title>
        <description>Chronic Graft-Versus-Host Disease is a severe long-term complication created by infusion of donor cells into a foreign host.</description>
        <time_frame>1 Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Marrow Isolex</title>
            <description>bone marrow processed using Isolex 300i (for patients enrolled through April 2010)</description>
          </group>
          <group group_id="O2">
            <title>UCB Arm</title>
            <description>No processing</description>
          </group>
          <group group_id="O3">
            <title>Marrow Clinimax</title>
            <description>bone marrow processed using CliniMACS (for patients enrolled beginning with the August 2010 protocol version)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Chronic Graft-Versus-Host Disease (GVHD)</title>
          <description>Chronic Graft-Versus-Host Disease is a severe long-term complication created by infusion of donor cells into a foreign host.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Transplant Related Deaths</title>
        <description>In the field of transplantation, toxicity is high and all deaths without previous relapse or progression are usually considered as related to transplantation</description>
        <time_frame>Day 100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Marrow Isolex</title>
            <description>bone marrow processed using Isolex 300i (for patients enrolled through April 2010)</description>
          </group>
          <group group_id="O2">
            <title>UCB Arm</title>
            <description>No processing</description>
          </group>
          <group group_id="O3">
            <title>Marrow Clinimax</title>
            <description>bone marrow processed using CliniMACS (for patients enrolled beginning with the August 2010 protocol version)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Transplant Related Deaths</title>
          <description>In the field of transplantation, toxicity is high and all deaths without previous relapse or progression are usually considered as related to transplantation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Marrow Isolex</title>
          <description>bone marrow processed using Isolex 300i (for patients enrolled through April 2010)</description>
        </group>
        <group group_id="E2">
          <title>UCB Arm</title>
          <description>No processing</description>
        </group>
        <group group_id="E3">
          <title>Marrow Clinimax</title>
          <description>bone marrow processed using CliniMACS (for patients enrolled beginning with the August 2010 protocol version)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <description>hemorrhage in the upper GI tract</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemolysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrect</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Cardiopumonary shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ototoxicity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Graft failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver Ischemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="27" subjects_affected="7" subjects_at_risk="16"/>
                <counts group_id="E2" events="13" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E3" events="10" subjects_affected="4" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Elevaed ALT</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Elevaed bilirubin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain Infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypoxic ischemic encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Neurotoxicity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Intubation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pulmonary hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Respiratory acidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Margaret L. MacMillan, M.D.</name_or_title>
      <organization>Masonic Cancer Center, University of Minnesota</organization>
      <phone>612-273-2800</phone>
      <email>macmi002@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

